Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs biosimilars - PubMed
a day ago
- #Inflammatory Bowel Disease
- #Clinical Remission
- #Biosimilars
- Biosimilars and originator biologics show comparable remission rates in IBD patients.
- No significant difference in time to remission between biosimilars (12.2 months) and originators (12.8 months).
- Similar rates of hospitalizations and emergency department visits for both treatment groups.
- Corticosteroid use and prior hospitalizations increase the risk of future hospitalizations.
- Study supports biosimilars as a cost-effective alternative to originator biologics in IBD management.